Breakthrough in Early Parkinson's Detection: Biomarkers Identified

A research team led by Chalmers University of Technology in Sweden has identified biomarkers for Parkinson's disease in its earliest stages. This discovery provides a limited window of opportunity for early diagnosis and potential future treatment, as these biological processes leave measurable traces in the blood before extensive brain damage occurs.

This discovery provides a limited window of opportunity for early diagnosis and potential future treatment, as these biological processes leave measurable traces in the blood before extensive brain damage occurs.

Parkinson's disease currently affects over 10 million people globally, a number projected to more than double by 2050. There is currently no effective cure or established screening method to detect the chronic neurological disorder before significant brain damage has taken place. Researchers noted that by the time motor symptoms appear, 50-80% of relevant brain cells are often already damaged.

Key Findings

The study, published in npj Parkinson's Disease, focused on two processes active in the early phase of the disease, which can precede motor symptoms by up to 20 years:

• DNA damage repair: The body's cellular system for detecting and correcting damage.
• Cells' stress response: A survival reaction that prioritizes repair and protection.

Using machine learning, the researchers identified a pattern of distinct gene activities linked to these processes in patients in the early phase of Parkinson's. This pattern was not present in healthy individuals or diagnosed patients with established symptoms. This suggests a crucial period for intervention.

Future Implications

The identified biomarkers can be measured in blood, paving the way for cost-effective and accessible broad screening tests. The research team anticipates that blood tests for early Parkinson's diagnosis could begin to be tested in healthcare within five years. In the long term, this research may contribute to the development of new drugs or the repurposing of existing drugs to prevent or treat the disease by targeting these early mechanisms.

About Parkinson's Disease

Parkinson's disease is a neurological disorder that impairs brain control over movement. It typically develops slowly, often after age 55-60, and is the second most common neurodegenerative disease worldwide after Alzheimer's. Early symptoms can include REM sleep behavior disorder, reduced sense of smell, constipation, depression, and anxiety. Later in the disease progression, motor symptoms such as slow movements, rigidity, instability, tremors, and involuntary muscle contractions may appear.